CORDIS · 101137207 · HORIZON
WAge Healthy Working environments for all Ages: An evidence-driven framework
Coordinator: SINTEF AS (NO)
The WAge project will develop and validate the first comprehensive framework for assessing and understanding the roles and interactions between physical and psychosocial risk factors across age groups through robust modelling and policy-relevant evidence gathering. Through the proposed framework, the project will pave the way for designing, implementing and validating effective multi-level intervention strategies and policy changes for workers of all ages at the individual and organizational level. The project focuses on a question that has high societal relevance and is timely because the pr…
About Horizon Europe (2021–2027)
Horizon Europe is the EU's current research and innovation programme, covering 2021 to 2027 with a budget of roughly €95.5 billion. Its three pillars are Excellent Science (frontier research and mobility), Global Challenges and European Industrial Competitiveness (mission-driven collaborative projects in health, climate, digital, security and food) and Innovative Europe (the EIC and EIT). It also funds five EU Missions targeting cancer, climate adaptation, smart cities, oceans and soils.
EU contribution: €5.4M awarded to the consortium. The project runs over approximately 4 years from 2023-12-01 to 2027-11-30.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu → Grant DOI ↗More from NO
see all →- COVID-19 VACCINES — PROPOSAL FOR FUNDING RESEARCH DEVELOPMENT AND MANUFACTURING OF VACCINE AGAINST COVID-19101018100 · H2020 · €100.0M
- CHIKVAX_CHIM — Late-stage clinical development of Chikungunya vaccines in endemic countries (CHIKV) and Controlled Human Infection Models for SARS-CoV2 and other beta coronaviruses (CHIM).101126531 · HORIZON · €70.0M
- ECRC — Developing a diverse portfolio of vaccine candidates for Rift Valley Fever, Chikungunya and Ebola857934 · H2020 · €36.0M
- FILOVAX — Development of Broadly Protective Filovirus Vaccines101167138 · HORIZON · €35.0M
- RIFTVAX — Clinical development of Rift Valley fever vaccines in endemic regions101081290 · HORIZON · €35.0M
- REFHYNE II — Clean Refinery Hydrogen for Europe II101036970 · H2020 · €32.4M
Other HORIZON projects
see all →- EUROfusion — Implementation of activities described in the Roadmap to Fusion during Horizon Europe through a joint programme of the members of the EUROfusion consortium101052200 · DE · €549.4M
- EITUM-BP26-28 — EIT Urban Mobility Business Plan 2026-2028101269525 · ES · €206.9M
- PARC — Partnership for the Assessment of Risks from Chemicals101057014 · FR · €200.0M
- EIT RM BP23-25 — EIT RawMatrials Business Plan 2023-2025101113034 · DE · €155.5M
- SGA1-HE — COST: Europe's most empowering research programme Strengthening science and innovation through research networking101052416 · BE · €153.0M
- EIT HEI — EIT Higher Education Initiative - Scaling Europe’s Innovation Ecosystems101270329 · DE · €130.0M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Horizon Europe (2021–2027) programme, under the HORIZON-RIA funding scheme.
- What is the EU contribution?
- The European Commission contributes €5.4M.
- Which EU programme funds it?
- The project is funded under Horizon Europe (2021–2027), call HORIZON-HLTH-2023-ENVHLTH-02.
- Who coordinates the project?
- The project is coordinated by SINTEF AS (NO).
- What is the project timeline?
- The project runs from 2023-12-01 to 2027-11-30 — approximately 4 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 101137207.